Goodwin Procter LLP advised Evox Therapeutics on the deal.
Evox Therapeutics, leading exosome therapeutics company, announced its £69.2 million Series C financing round. The financing was significantly oversubscribed with high demand from both existing and new investors.
The Series C financing was led by Redmile Group who were joined by new investors OrbiMed and Invus. In addition to Redmile, all existing Series B investors reinvested, including major investors Oxford Sciences Innovation (OSI), GV (formerly Google Ventures) and Cowen Healthcare Investments.
Proceeds from this financing will support the advancement of Evox’s exosome-based therapeutics pipeline, including progression of several rare disease assets into the clinic, and continued development of its world-leading DeliverEXTM exosome drug platform.
Evox Therapeutics is a privately held, Oxford-based biotechnology company focused on harnessing and engineering the natural delivery capabilities of extracellular vesicles, known as exosomes, to develop an entirely new class of therapeutics. Backed by leading life sciences venture capital groups and supported by a comprehensive intellectual property portfolio, Evox’s mission is to positively impact human health by creating novel exosome-based therapeutics for the treatment of various severe diseases with limited options for patients and their families.
The Goodwin team was led by David Mardle (Picture) and Elizabeth Rhodes.
Law Firms: Goodwin Procter;
Clients: Evox Therapeutics;